^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

LB080 / 5 - Tipifarnib prevents emergence of resistance to osimertinib in EGFR-mutant NSCLC

Published date:
03/09/2022
Excerpt:
Co-treatment with tipifarnib, a clinically active FTi, safely and durably prevented relapse to osimertinib in a PC9-xenograft model as well as in a PDX model of EGFR L858R/T790M lung cancer for up to 6 months with no evidence of toxicity.